贝达喹啉对鸟分枝杆菌复合群的体外药敏试验
In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
作者信息
Brown-Elliott Barbara A, Philley Julie V, Griffith David E, Thakkar Foram, Wallace Richard J
机构信息
Mycobacteria/Nocardia Research Laboratory, Department of Microbiology, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA
Department of Medicine, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01798-16. Print 2017 Feb.
Abstract
We performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 103 respiratory isolates of Mycobacterium avium complex (MAC), including multidrug-resistant isolates. Approximately 90% of isolates had bedaquiline MICs of ≤0.008 μg/ml, and 102/103 isolates had MICs of ≤0.015 μg/ml. Bedaquiline has excellent potential for use in patients with MAC infections, although for reasons of its metabolism by the cytochrome P450 system, it should not be given with rifampin.
摘要
我们按照临床和实验室标准协会（CLSI）的指南，对103株鸟分枝杆菌复合群（MAC）呼吸道分离株，包括耐多药分离株，进行了贝达喹啉肉汤微量稀释药敏试验。约90%的分离株贝达喹啉最低抑菌浓度（MIC）≤0.008μg/ml，103株中有102株MIC≤0.015μg/ml。贝达喹啉在MAC感染患者中具有很好的应用潜力，不过由于其经细胞色素P450系统代谢，不应与利福平合用。
相似文献
1
In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01798-16. Print 2017 Feb.
2
activity of bedaquiline against complex.
J Med Microbiol. 2021 Oct;70(10). doi: 10.1099/jmm.0.001439.
3
Bedaquiline susceptibility testing of Mycobacterium abscessus complex and Mycobacterium avium complex: A meta-analysis study.
J Glob Antimicrob Resist. 2024 Jun;37:135-140. doi: 10.1016/j.jgar.2024.03.009. Epub 2024 Mar 30.
4
In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
J Clin Microbiol. 2013 Oct;51(10):3389-94. doi: 10.1128/JCM.01612-13. Epub 2013 Aug 14.
5
Difference in drug susceptibility distribution and clinical characteristics between and lung diseases in Shanghai, China.
J Med Microbiol. 2021 May;70(5). doi: 10.1099/jmm.0.001358.
6
Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
J Infect Chemother. 2018 Apr;24(4):315-318. doi: 10.1016/j.jiac.2017.10.022. Epub 2017 Dec 7.
7
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.
8
Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
J Infect Chemother. 2019 Dec;25(12):995-1000. doi: 10.1016/j.jiac.2019.05.028. Epub 2019 Jun 22.
9
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
10
In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
J Microbiol Immunol Infect. 2018 Oct;51(5):636-643. doi: 10.1016/j.jmii.2017.05.001. Epub 2017 Jun 28.
引用本文的文献
1
Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against in the hollow-fiber system.
Antimicrob Agents Chemother. 2025 May 7;69(5):e0146424. doi: 10.1128/aac.01464-24. Epub 2025 Apr 14.
2
Curcumin enhances bedaquiline's efficacy against : and evidence.
Microbiol Spectr. 2025 Mar 18;13(5):e0229524. doi: 10.1128/spectrum.02295-24.
3
Treatment for non-tuberculous mycobacteria: challenges and prospects.
Front Microbiol. 2024 Jun 3;15:1394220. doi: 10.3389/fmicb.2024.1394220. eCollection 2024.
4
Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.
J Antimicrob Chemother. 2024 Feb 1;79(2):211-240. doi: 10.1093/jac/dkad372.
5
In Vitro Effect of Three-Antibiotic Combinations plus Potential Antibiofilm Agents against Biofilm-Producing and Clinical Isolates.
Antibiotics (Basel). 2023 Sep 6;12(9):1409. doi: 10.3390/antibiotics12091409.
6
Variability of Complex Isolates Drug Susceptibility Testing by Broth Microdilution.
Antibiotics (Basel). 2022 Dec 4;11(12):1756. doi: 10.3390/antibiotics11121756.
7
Development of Human Cell-Based Infection Models to Determine the Intracellular Survival of .
Front Cell Infect Microbiol. 2022 Jun 24;12:872361. doi: 10.3389/fcimb.2022.872361. eCollection 2022.
8
In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.
BMC Microbiol. 2022 Jul 8;22(1):175. doi: 10.1186/s12866-022-02582-2.
9
Looking beyond Typical Treatments for Atypical Mycobacteria.
Antibiotics (Basel). 2020 Jan 3;9(1):18. doi: 10.3390/antibiotics9010018.
10
Inhaled Antibiotics for Mycobacterial Lung Disease.
Pharmaceutics. 2019 Jul 19;11(7):352. doi: 10.3390/pharmaceutics11070352.
本文引用的文献
1
Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.
Chest. 2015 Aug;148(2):499-506. doi: 10.1378/chest.14-2764.
2
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21.
3
A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
Eur Respir J. 2015 Feb;45(2):554-7. doi: 10.1183/09031936.00142914. Epub 2014 Oct 30.
4
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
Clin Infect Dis. 2015 Jan 15;60(2):188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15.
5
Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
N Engl J Med. 2014 Aug 21;371(8):723-32. doi: 10.1056/NEJMoa1313865.
6
FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
N Engl J Med. 2014 Aug 21;371(8):689-91. doi: 10.1056/NEJMp1314385.
7
Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2014 May;58(5):2979-81. doi: 10.1128/AAC.00037-14. Epub 2014 Mar 3.
8
Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Chest. 2014 Aug;146(2):276-282. doi: 10.1378/chest.13-2538.
9
Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.
Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9. doi: 10.1128/AAC.01124-13. Epub 2013 Sep 23.
10
Bedaquiline: First FDA-approved tuberculosis drug in 40 years.
Int J Appl Basic Med Res. 2013 Jan;3(1):1-2. doi: 10.4103/2229-516X.112228.
Zotero 插件